No new shares of common stock being sold by the Company
BOULDER, Colo.--(BUSINESS WIRE)--Dec. 2, 2013--
Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that certain
selling stockholders have commenced an underwritten public offering of
2,000,000 shares of the Company’s common stock which they recently
acquired as consideration in connection with the Company’s acquisition
of EOS (Ethical Oncology Science) S.p.A.
All net proceeds from the sale of the common stock will be received by
the selling stockholders. The Company will not receive any of the
proceeds, and the total number of shares of its outstanding common stock
will not change as a result of the offering.
J. P. Morgan Securities LLC is acting as the sole manager for the
offering. In addition, the selling stockholders intend to grant J. P.
Morgan Securities LLC a 30-day option to purchase up to an additional 15
percent of the number of shares sold to cover over-allotments, if any.
The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
This offering is being made only by means of a prospectus and related
prospectus supplement, copies of which may be obtained from J. P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.
The shares are being offered by the selling stockholders pursuant to an
effective shelf registration statement. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such state or other jurisdiction.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops diagnostic tools that direct a
compound in development to the population that is most likely to benefit
from its use. Clovis Oncology is headquartered in Boulder, Colorado, and
has additional offices in San Francisco, California and Cambridge, UK.
Source: Clovis Oncology, Inc.
Clovis Oncology, Inc.
Anna Sussman, 303-625-5022